The HIF1A Knockout HCT 116 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered from the HCT 116 human colorectal carcinoma cell line, offering a versatile loss-of-function model for studying HIF1A-mediated hypoxia responses. This heterogeneous pool of knockout cells carries targeted gene disruptions within HIF1A, enabling functional investigations without clonal bias.
The HCT 116 parental cell line is an epithelial tumor line derived from a male colorectal cancer patient, widely recognized for its KRAS mutation and microsatellite instability (MSI) phenotype. These genetic features make HCT 116 particularly valuable for exploring oncogenic signaling and the cellular adaptation to hypoxic microenvironments often encountered in solid tumors.
HIF1A encodes the alpha subunit of the hypoxia-inducible factor-1 (HIF-1) transcription complex, a master regulator of adaptive responses to low oxygen tension. Under normoxia, HIF1A is hydroxylated by prolyl hydroxylases (PHD1, PHD2, PHD3) and subsequently recognized by the VHL E3 ligase, leading to ubiquitin-dependent proteasomal degradation. Hypoxia inhibits hydroxylation, allowing HIF1A to accumulate, translocate to the nucleus, and dimerize with ARNT (HIF1B). The active complex recruits coactivators p300/CBP and binds hypoxia response elements (HREs) to drive transcription of genes such as VEGF, GLUT1, PDK1, CA9, and LDHA, which orchestrate angiogenesis, metabolic reprogramming, and cell survival. HIF1A stability and activity are further modulated by interacting proteins including HSP90, p53, STAT3, and regulated by upstream signals from growth factors (EGF, IGF-1), cytokines (TNF-alpha, IL-1beta), and the PI3K/AKT/mTOR pathway.
Disruption of HIF1A in the HCT 116 background provides a powerful system to dissect the contribution of HIF-1 signaling to colorectal cancer progression. Given the presence of an activating KRAS mutation and defective mismatch repair, this knockout model enables dissection of crosstalk between oncogenic pathways and hypoxia responses, and facilitates study of hypoxia-driven angiogenesis, glycolytic switch, and resistance to chemotherapy. It is particularly relevant for investigating how tumor cells survive and proliferate under the low oxygen conditions typical of the tumor microenvironment.
These polyclonal knockout cells are suitable for a wide range of experimental approaches to probe HIF-1 function. Researchers can perform western blotting for HIF1A and target proteins following exposure to hypoxia or chemical mimetics (CoCl2, DMOG), HRE-luciferase reporter gene assays, ChIP-qPCR to quantify HIF1A binding to HREs, and immunofluorescence to visualize nuclear accumulation. Functional studies may include migration and invasion assays, colony formation under hypoxia, and metabolic analyses such as lactate production and glucose uptake. The cells also serve as a platform for screening HIF-1 inhibitors or testing therapeutic agents targeting the hypoxic response. For additional details, please contact Ascent Research.
